Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting
In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 August 2012
|
| In: |
Annals of hematology
Year: 2012, Jahrgang: 91, Heft: 11, Pages: 1765-1772 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-012-1534-y |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00277-012-1534-y Verlag, Volltext: https://doi.org/10.1007/s00277-012-1534-y 
|
| Verfasserangaben: | M. Witzens-Harig, G. Hess, J. Atta, M. Zaiss, G. Lenz, C. Scholz, R. Repp, M. Reiser, C. Pott, H. Pelz, P. La Rosée, H. Kirchner, P. Kiewe, U. Keller, C. Buske, A. Viardot, M. Dreyling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580427219 | ||
| 003 | DE-627 | ||
| 005 | 20230427065659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180827s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-012-1534-y |2 doi | |
| 035 | |a (DE-627)1580427219 | ||
| 035 | |a (DE-576)510427219 | ||
| 035 | |a (DE-599)BSZ510427219 | ||
| 035 | |a (OCoLC)1341017724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 245 | 1 | 0 | |a Current treatment of mantle cell lymphoma |b results of a national survey and consensus meeting |c M. Witzens-Harig, G. Hess, J. Atta, M. Zaiss, G. Lenz, C. Scholz, R. Repp, M. Reiser, C. Pott, H. Pelz, P. La Rosée, H. Kirchner, P. Kiewe, U. Keller, C. Buske, A. Viardot, M. Dreyling |
| 264 | 1 | |c 29 August 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.08.2018 | ||
| 520 | |a In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival in younger patients. In elderly patients, rituximab maintenance led to a marked prolongation of remission duration. Emerging strategies include mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, immune modulatory drugs, Bruton’s tyrosine kinase inhibitors and others, all based on the dysregulated control of cell cycle machinery and impairment of several apoptotic pathways. Combination strategies are currently being investigated in numerous trials, but their introduction into clinical practice and current treatment algorithms remains a challenge. In the current survey, the application of the molecular targeted compounds were collected and evaluated by a representative national network of 14 haematological institutions. Optimised strategies are recommended for clinical routine. Future studies will apply individualised approaches according to the molecular risk profile of the patient. | ||
| 650 | 4 | |a Consensus meeting | |
| 650 | 4 | |a Current treatment | |
| 650 | 4 | |a Mantle cell lymphoma | |
| 650 | 4 | |a National survey | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 91(2012), 11, Seite 1765-1772 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a Current treatment of mantle cell lymphoma results of a national survey and consensus meeting |
| 773 | 1 | 8 | |g volume:91 |g year:2012 |g number:11 |g pages:1765-1772 |g extent:8 |a Current treatment of mantle cell lymphoma results of a national survey and consensus meeting |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-012-1534-y |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00277-012-1534-y |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180827 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1580427219 |e 3023899460 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["M. Witzens-Harig, G. Hess, J. Atta, M. Zaiss, G. Lenz, C. Scholz, R. Repp, M. Reiser, C. Pott, H. Pelz, P. La Rosée, H. Kirchner, P. Kiewe, U. Keller, C. Buske, A. Viardot, M. Dreyling"]},"id":{"doi":["10.1007/s00277-012-1534-y"],"eki":["1580427219"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"29 August 2012"}],"relHost":[{"title":[{"subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title":"Annals of hematology","title_sort":"Annals of hematology"}],"pubHistory":["62, 1 (Februrary 1991)-"],"titleAlt":[{"title":"Hematology"}],"part":{"pages":"1765-1772","issue":"11","year":"2012","extent":"8","text":"91(2012), 11, Seite 1765-1772","volume":"91"},"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"disp":"Current treatment of mantle cell lymphoma results of a national survey and consensus meetingAnnals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"253389852","origin":[{"publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedKey":"1991","publisher":"Springer","dateIssuedDisp":"1991-"}],"id":{"issn":["1432-0584"],"eki":["253389852"],"zdb":["1458429-3"]},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"8 S."}],"person":[{"family":"Witzens-Harig","given":"Mathias","roleDisplay":"VerfasserIn","display":"Witzens-Harig, Mathias","role":"aut"}],"title":[{"title":"Current treatment of mantle cell lymphoma","subtitle":"results of a national survey and consensus meeting","title_sort":"Current treatment of mantle cell lymphoma"}],"recId":"1580427219","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 27.08.2018"]} | ||
| SRT | |a WITZENSHARCURRENTTRE2920 | ||